| [1] |
中华医学会妇产科学分会产科学组，中华医学会围产医学分会．产后出血预防与处理指南(2023)[J]．中华妇产科杂志，2023，58(6): 401-409.
|
| [2] |
World Health Organization. A roadmap to combat postpartum haemorrhage between 2023 and 2030. Geneva: WHO，2023：68.
|
| [3] |
Quintana DS, Rokicki J, van der Meer D, et al. Oxytocin pathway gene networks in the human brain[J]. Nat Commun，2019，10(1)：668.
|
| [4] |
Uvnäs-Moberg K, Ekström-Bergström A, Berg M, et al. Maternal plasma levels of oxytocin during physiological childbirth-a systematic review with implications for uterine contractions and central actions of oxytocin[J]. BMC Pregnancy Childbirth，2019，19(1)：285.
|
| [5] |
Uvnäs-Moberg K. The physiology and pharmacology of oxytocin in labor and in the peripartum period[J]. Am J Obstet Gynecol，2024，230(3S)：S740-S758.
|
| [6] |
Dale HH. On some physiological actions of ergot[J]. J Physiol，1906，34(3)：163-206.
|
| [7] |
du Vigneaud V, Ressler C, Swan CJ, et al. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc，1953，75(19)：4879-4880.
|
| [8] |
du Vigneaud V, Ressler C, Trippett S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin[J]. J Biol Chem，1953，205(2)：949-957.
|
| [9] |
Balki M, Tsen L. Oxytocin protocols for cesarean delivery[J]. Int Anesthesiol Clin, 2014，52(2)：48-66.
|
| [10] |
de Groot AN, van Dongen PW, Vree TB, et al. Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology[J]. Drugs，1998，56(4)：523-535.
|
| [11] |
Arias F. Pharmacology of oxytocin and prostaglandins[J]. Clin Obstet Gynecol，2000，43(3)：455-468.
|
| [12] |
Uvnäs Moberg K, Ekström-Bergström A, Buckley S, et al. Maternal plasma levels of oxytocin during breastfeeding-a systematic review. PLoS One，2020，15(8)：e0235806.
|
| [13] |
Jankowski M, Broderick TL, Gutkowska J. The Role of oxytocin in cardiovascular protection[J]. Front Psychol，2020，11：2139.
|
| [14] |
Hermesch AC, Kernberg AS, Layoun VR, et al. Oxytocin: physiology, pharmacology, and clinical application for labor management[J]. Am J Obstet Gynecol，2024，230(3S)：S729-S739.
|
| [15] |
Burbach JPH, Young LJ, Russell JA. Oxytocin synthesis, secretion, and reproductive functions//Jimmy D. Neill, Knobil and Neill′s Physiology of Reproduction. 3rd ed, Pittsburgh: Academic Press，2006: 3055-3128.
|
| [16] |
Gallos ID, Papadopoulou A, Man R, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis[J]. Cochrane Database Syst Rev，2018，12(12)：CD011689.
|
| [17] |
Sentilhes L, Goffinet F, Vayssière C, et al. Comparison of postpartum haemorrhage guidelines: discrepancies underline our lack of knowledge[J]. BJOG，2017，124(5)：718-722.
|
| [18] |
World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: World Health Organization，2012：1-37.
|
| [19] |
Rath W. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin[J]. Eur J Obstet Gynecol Reprod Biol，2009，147(1)：15-20.
|
| [20] |
Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus[J]. Clin Pharmacol Ther，1992，52(1)：60-67.
|
| [21] |
Robinson D, Basso M, Chan C, et al. Guideline No. 431: postpartum hemorrhage and hemorrhagic shock[J]. J Obstet Gynaecol Can，2022，44(12)：1293-1310.e1.
|
| [22] |
刘兴会，陈锰. 基于大数据的产后出血临床处理[J]. 中国实用妇科与产科杂志，2018，34(1)：33-37.
|
| [23] |
Martillotti G, Talajic M, Rey E, et al. Long QT syndrome in pregnancy: are vaginal delivery and use of oxytocin permitted? A case report[J]. J Obstet Gynaecol Can，2012，34(11)：1073-1076.
|
| [24] |
Heesen M, Carvalho B, Carvalho J, et al. International consensus statement on the use of uterotonic agents during caesarean section[J]. Anaesthesia，2019，74(10)：1305-1319.
|
|
Giouleka S, Tsakiridis I, Kalogiannidis I, et al. Postpartum hemorrhage: a comprehensive review of guidelines[J]. Obstet Gynecol Surv，2022，77(11)：665-682.
|
| [25] |
Saccone G, Della Corte L, D′Alessandro P, et al. Prophylactic use of tranexamic acid after vaginal delivery reduces the risk of primary postpartum hemorrhage[J]. J Matern Fetal Neonatal Med，2020，33(19)：3368-3376.
|
| [27] |
Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage[J]. Cochrane Database Syst Rev，2015(6)：CD007872.
|
| [28] |
Gungorduk K, Asıcıoǧlu O, Yıldırım G, et al. Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study[J]. Am J Perinatol，2013，30(5)：407-413.
|
| [29] |
Karasu Y, Demeli Ertuş M, Önal D, et al. In vitro inhibition of uterine contractions using electrospun nanofibers loaded with nifedipine and ML7[J]. Eur Rev Med Pharmacol Sci，2024，28(5)：1891-1903.
|
| [30] |
中华医学会妇产科学分会产科学组，中华医学会围产医学分会. 正常分娩指南[J]. 中华妇产科杂志，2020, 55(6): 361-370.
|
| [31] |
Moen V, Brudin L, Rundgren M, et al. Hyponatremia complicating labour－－rare or unrecognised? A prospective observational study[J]. BJOG，2009，116(4)：552-561.
|
| [32] |
Bergum D, Lonnée H, Hakli TF. Oxytocin infusion: acute hyponatraemia, seizures and coma[J]. Acta Anaesthesiol Scand，2009，53(6)：826-827.
|
| [33] |
Butwick AJ, Coleman L, Cohen SE, et al. Minimum effective bolus dose of oxytocin during elective Caesarean delivery[J]. Br J Anaesth，2010，104(3)：338-343.
|
| [34] |
Dyer RA, Butwick AJ, Carvalho B. Oxytocin for labour and caesarean delivery: implications for the anaesthesiologist[J]. Curr Opin Anaesthesiol，2011，24(3)：255-261.
|
| [35] |
Kreifels P, Bodi I, Hornyik T, et al. Oxytocin exerts harmful cardiac repolarization prolonging effects in drug-induced LQTS[J]. Int J Cardiol Heart Vasc，2022，40：101001.
|